CITY THERAPEUTICS, INC.

S-1 filed

City Therapeutics, Inc. is preparing for its IPO, as outlined in the S-1 filing, with a focus on its collaboration revenue from Bausch + Lomb and Biogen. The company reported a significant increase in collaboration revenue to $13.6 million for 2025, driven by new agreements and expanded research activities. However, it continues to operate at a loss, with research and development expenses rising to $58.4 million and general and administrative expenses to $15.1 million. The company emphasizes its reliance on external funding, noting that its current cash reserves, supplemented by the IPO proceeds, will only cover operations until a specific date. The filing highlights ongoing financial challenges, including the need for additional capital and the risks associated with its unproven product candidates.

DRS/A amended

City Therapeutics, Inc. provides detailed disclosures on its accounting policies, including stock-based compensation, convertible preferred stock classification, and revenue recognition under ASC 606. The filing highlights recent adoption of accounting standards (ASU 2023-09 and ASU 2024-04) and emphasizes its financial losses for 2024 and 2025. The company's convertible preferred stock is classified as mezzanine equity due to redemption risks, and revenue recognition focuses on performance obligations and milestone payments.

DRS filed

City Therapeutics, Inc. discloses its financial policies and accounting practices in its DRS filing, including the classification of convertible preferred stock as mezzanine equity, revenue recognition under ASC 606, and research and development expense accounting. The filing highlights the company's adherence to accounting standards, with specific attention to stock-based compensation, convertible debt, and income tax disclosures. Recent accounting updates, such as ASU 2023-09 and ASU 2024-04, are noted, reflecting compliance with evolving regulatory requirements.